Cardiovascular Systems Expands Product Portfolio Company to Sell Invatec Balloon Catheters in the United States

ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, has expanded its product portfolio by signing an agreement with Invatec, a comprehensive provider of interventional products, to market Invatec’s PTA balloon catheter line in the United States. CSI is also launching the newest addition to its Viper line of supplemental products, the ViperSheath™ Introducer Sheath.

CSI’s flagship product is the Diamondback 360o™ Orbital Atherectomy System, a minimally invasive catheter system for treating peripheral arterial disease (PAD). Between 8 and 12 million Americans suffer from PAD, which is caused by the accumulation of plaque in leg or foot arteries, reducing blood flow. Symptoms include leg pain when walking or at rest, and PAD can lead to tissue loss and eventually limb amputation. The Diamondback 360o is highly effective in removing plaque and restoring blood flow in vessels both below and above the knee. In some cases, balloon angioplasty may also be used to achieve the desired vessel diameter after removing plaque with the Diamondback 360o.

Full text >> http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20090408005258&newsLang=en